respiratori
virus
influenzalik
ill
epidemiolog
outcom
children
age
month
year
multicountri
popul
sampl
introduct
acut
respiratori
tract
infect
arti
compris
common
ill
worldwid
children
often
experi
sever
episod
year
children
clinic
present
rang
mild
uncompl
upper
respiratori
tract
ill
sever
lower
respiratori
tract
infect
lrti
includ
pneumonia
bronchiol
croup
exacerb
asthma
wheez
world
health
organ
estim
million
children
die
arti
africa
south
east
asia
pneumonia
alon
led
million
death
worldwid
children
less
year
age
arti
caus
virus
advent
multiplex
polymeras
chain
reaction
pcr
techniqu
often
possibl
identifi
accur
specif
viral
infect
clinic
case
pathogen
consid
respons
arti
respiratori
syncyti
viru
rsv
influenza
b
parainfluenza
virus
type
adenoviru
sever
new
pathogen
associ
arti
identifi
recent
includ
human
metapneumoviru
hmpv
rhinoviru
coronaviru
human
bocaviru
hbov
parainfluenza
vaccin
efficaci
trial
provid
intens
activ
followup
welldefin
popul
use
evalu
viral
epidemiolog
part
trial
pandem
influenza
vaccin
includ
year
prospect
activ
communitybas
surveil
influenzalik
ill
ili
center
eight
countri
evalu
preval
incid
respiratori
virus
children
month
less
year
age
first
vaccin
sampl
obtain
efficaci
trial
two
pandem
influenza
vaccin
sponsor
gsk
vaccin
analysi
estim
preval
rsv
ili
previous
report
report
data
respiratori
virus
evalu
secondari
analysi
object
healthi
children
month
year
age
enrol
random
observerblind
parallel
group
multicountri
trial
versu
nonadjuv
monoval
pandem
vaccin
trial
conduct
center
australia
brazil
colombia
costa
rica
mexico
philippin
singapor
thailand
februari
august
enrol
took
month
time
vari
countri
trial
approv
institut
review
board
center
written
inform
consent
obtain
parentsguardian
parent
instruct
contact
studi
center
within
h
child
becam
ill
activ
surveil
via
script
telephon
contact
conduct
week
first
vaccin
contact
made
everi
week
day
child
regardless
time
enrol
ili
defin
temperatur
c
rout
least
one
new
worsen
cough
sore
throat
stuffi
nose
runni
nose
studi
staff
visit
child
home
collect
one
anterior
nasal
swab
one
throat
swab
ideal
within
h
ili
onset
within
day
collect
could
also
take
place
studi
center
hospit
necessari
swab
transport
singl
tube
transport
medium
store
c
maintain
dri
ice
transport
symptomfre
period
requir
new
ili
episod
sampl
test
perform
standard
multiplex
pcr
techniqu
analysi
viral
epidemiolog
virus
evalu
influenza
subtyp
b
parainfluenza
subtyp
rsv
subtyp
b
hmpv
rhinovirusenteroviru
assay
distinguish
adenoviru
coronaviru
subtyp
hbov
first
analyz
separ
influenza
parainfluenza
coronaviru
subtyp
group
posthoc
analysi
main
outcom
variabl
pcrconfirm
infect
state
virus
nasalthroat
swab
children
ili
includ
infect
viru
consider
alon
singl
infect
viru
consider
plu
one
virus
coinfect
singl
coinfect
also
record
separ
clinic
characterist
ili
episod
report
parent
children
hospit
medic
attend
doctor
healthcar
profession
includ
sampl
collect
studi
staff
record
pneumonia
defin
acut
ill
one
fever
c
new
worsen
cough
dyspnea
consist
auscult
find
rale
diminish
breath
sound
pain
chest
abdomen
breath
purul
bloodstain
sputum
product
radiolog
find
consist
pneumonia
total
cohort
includ
children
enrol
random
trial
total
cohort
ili
episod
test
multiplex
pcr
includ
children
enrol
experienc
ili
adequ
nasalthroat
sampl
test
multiplex
pcr
analysi
preval
respiratori
virus
ili
clinic
characterist
associ
ili
perform
total
cohort
ili
episod
test
multiplex
pcr
analysi
overal
incid
ili
medicallyattend
ili
hospit
ili
respiratori
virus
detect
perform
total
cohort
preval
respiratori
virus
among
ili
episod
calcul
x
number
ili
episod
nasalthroat
sampl
posit
viru
n
total
number
ili
episod
sampl
collect
within
day
test
least
day
two
ili
episod
assum
episod
independ
exact
confid
interv
ci
comput
preval
stratifi
accord
countri
age
time
ili
episod
month
whether
child
medic
attend
hospit
incid
per
personyear
py
virusassoci
ili
studi
popul
calcul
n
total
number
children
enrol
trial
total
number
virusposit
ili
episod
subject
followup
period
subject
incid
rate
stratifi
accord
countri
age
group
time
ili
episod
exact
poisson
ci
calcul
observ
incomplet
data
outcom
variabl
ili
episod
nasal
throat
sampl
taken
remov
analysi
miss
data
account
calcul
miss
proport
countri
age
group
multipli
py
minu
miss
proport
trial
includ
children
total
cohort
exclud
children
ili
inadequ
sampl
children
experienc
ili
episod
total
cohort
ili
episod
test
multiplex
pcr
particip
flow
shown
supplement
fig
demograph
similar
cohort
except
children
total
cohort
older
median
versu
month
supplement
tabl
respiratori
viru
detect
ili
episod
rhinovirusenteroviru
highest
overal
preval
follow
influenza
adenoviru
parainfluenza
rsv
coronaviru
hmpv
hbov
tabl
coinfect
detect
often
adenoviru
hbov
fig
singl
infect
parainfluenza
hmpv
coronaviru
identifi
approxim
frequenc
coinfect
fig
howev
parainfluenza
coronaviru
identifi
often
coinfect
whilst
coronaviru
identifi
often
singl
infect
supplement
tabl
countri
rhinovirusenteroviru
preval
whilst
hbov
least
preval
tabl
influenza
preval
rang
parainfluenza
preval
approxim
except
brazil
singapor
tabl
tabl
influenza
preval
oldest
children
month
follow
month
age
group
tabl
virus
least
preval
oldest
group
tabl
less
obviou
pattern
age
group
gener
preval
declin
age
except
influenza
tabl
incid
detect
respiratori
virus
associ
ili
reflect
preval
overal
incid
per
py
total
cohort
children
random
rhinovirusenteroviru
influenza
adenoviru
parainfluenza
rsv
coronaviru
hmpv
hbov
tabl
australia
highest
incid
hmpv
second
highest
rsv
low
incid
virus
rel
countri
tabl
philippin
singapor
thailand
also
low
incid
virus
ili
rel
latin
american
countri
tabl
detect
respiratori
virus
differ
time
year
highli
variabl
across
countri
fig
overal
incid
medicallyattend
ili
associ
viral
infect
per
py
total
cohort
children
random
rang
hbov
rhinovirusenteroviru
tabl
correspond
valu
incid
hospit
ili
associ
viral
infect
hbov
rhinovirusenteroviru
tabl
clinic
characterist
ili
episod
associ
singl
respiratori
viru
ie
coinfect
shown
tabl
median
durat
ili
episod
rang
day
children
hospit
medic
attend
outsid
studi
procedur
percentag
children
miss
school
daycar
highest
influenzaassoci
ili
follow
hmpv
adenoviru
rhinovirusenteroviru
coronaviru
rsv
parainfluenza
hbov
tabl
sore
throat
experienc
children
cough
stuffi
nose
runni
nose
tabl
fever
part
ili
definit
therefor
experienc
children
cough
report
almost
children
influenza
parainfluenza
rsv
hmpv
coronaviru
infect
children
rhinoviru
enteroviru
adenoviru
hbov
infect
medic
import
differ
clinic
characterist
children
singl
viral
infect
compar
children
multipl
infect
supplement
tabl
total
pneumonia
case
identifi
among
children
enrol
overal
clinic
trial
correspond
detect
rate
case
met
definit
ili
therefor
elig
sampl
collect
per
clinic
trial
protocol
sampl
collect
within
day
onset
ili
symptom
case
one
case
thailand
three
philippin
five
brazil
five
mexico
six
colombia
tabl
viru
detect
three
case
singl
infect
detect
case
four
rhinovirusenteroviru
two
parainfluenza
one
influenza
two
rsv
one
hmpv
coinfect
detect
seven
case
tabl
nine
children
hospit
rhinovirusenteroviru
highest
preval
incid
ili
respiratori
virus
test
countri
follow
influenza
adenoviru
parainfluenza
rsv
coronaviru
hmpv
hbov
burden
ili
associ
respiratori
virus
consider
high
proport
children
seen
medic
profession
mani
miss
school
daycar
analysi
benefit
part
clinic
trial
previous
describ
importantli
conduct
year
prospect
activ
commun
surveil
healthi
children
tropic
southern
hemispher
countri
prospect
data
lack
studi
viral
epidemiolog
use
hospitalbas
surveil
communitybas
surveil
difficult
expens
howev
hospitalbas
surveil
tend
captur
sever
ill
mani
case
miss
develop
countri
limit
hospit
access
analysi
avoid
limit
allow
us
captur
burden
virusassoci
ili
commun
understand
commun
epidemiolog
essenti
implement
effect
control
measur
advantag
part
clinic
trial
includ
wellcharacter
popul
wide
age
rang
year
sampl
taken
high
proport
children
consist
methodolog
countri
use
sensit
valid
pcr
assay
trial
conduct
eight
countri
encompass
australia
south
east
asia
latin
america
exact
time
enrol
vari
somewhat
countri
plan
data
collect
perform
peak
influenza
season
individu
countri
state
method
children
follow
day
complet
period
surveil
studi
occur
februari
august
allow
us
compar
distribut
virus
across
differ
countri
consider
variat
incid
preval
virus
countri
although
rhinovirusenteroviru
far
highest
incid
preval
countri
hbov
consist
lowest
incid
preval
sever
studi
evalu
preval
virus
children
respiratori
ill
rel
preval
differ
circul
virus
vari
studi
howev
main
circul
virus
similar
studi
studi
includ
picornavirus
includ
rhinoviru
adenoviru
rsv
bocaviru
piv
hmpv
influenza
coronaviru
rhinovirus
classifi
picornaviru
famili
enteroviru
genu
high
preval
famili
report
studi
differ
set
studi
australian
studi
activ
communitybas
surveil
healthi
preschoolag
children
arti
found
picornavirus
includ
rhinovirus
frequent
detect
howev
virus
detect
less
frequent
studi
rsv
parainfluenza
influenza
hmpv
adenoviru
coronaviru
anoth
prospect
australian
studi
children
age
month
year
report
ili
rhinoviru
commonli
detect
howev
contrast
result
adenoviru
detect
frequenc
rhinoviru
follow
parainfluenza
polyomaviru
hmpv
hbov
influenza
rsv
rel
uncommon
approxim
children
fulli
partial
vaccin
influenza
rhinoviru
alway
commonli
detect
viru
children
respiratori
diseas
children
year
age
hospit
lrti
thailand
commonli
detect
virus
rsv
rhinoviru
hbov
influenza
studi
children
age
year
hospit
lrti
brazil
found
rsv
preval
episod
follow
hmpv
rhinoviru
influenza
hbov
parainfluenza
adenoviru
coronaviru
analysi
influenza
preval
increas
age
virus
show
opposit
trend
lowest
preval
observ
oldest
children
month
less
obviou
pattern
younger
age
gener
preval
virus
except
influenza
declin
age
despit
burden
ill
remain
consider
older
children
clear
season
pattern
influenza
rsv
hmpv
countri
lesser
extent
rhinoviru
enteroviru
previou
studi
found
although
clear
season
peak
rhinovirusenteroviru
onset
seem
correspond
start
school
year
usa
limit
one
year
analysi
human
rhinovirus
enterovirus
ili
latin
america
show
yearround
tempor
distribut
throughout
central
south
america
howev
human
rhinoviru
c
speci
display
opposit
season
trend
either
side
equat
account
higher
percentag
ili
case
north
equat
septemb
januari
south
equat
detect
increas
april
juli
part
studi
children
receiv
monoval
influenza
pandem
vaccin
one
two
dose
vaccin
administ
two
dose
unadjuv
vaccin
trival
season
influenza
vaccin
rate
present
studi
approxim
influenza
subtyp
isol
children
influenza
subtyp
isol
children
influenza
b
isol
children
differ
studi
vaccin
group
observ
case
associ
influenza
least
like
coinfect
respiratori
virus
rhinoviru
enteroviru
also
common
singl
infect
adenoviru
hbov
found
often
coinfect
bacteri
coinfect
measur
part
studi
usbas
influenza
incid
surveil
project
evalu
commonli
detect
virus
outpati
arti
ili
threequart
coinfect
involv
adenoviru
rhinovirusenteroviru
ukbas
analysi
found
neg
associ
influenza
hmpv
influenza
rhinoviru
posit
associ
found
parainfluenza
rhinoviru
rsv
rhinoviru
adenoviru
rhinoviru
parainfluenza
rsv
correl
found
coinfect
clinic
sever
studi
brazil
evalu
children
year
sought
medic
care
respiratori
tract
infect
research
need
understand
interact
respiratori
virus
host
respons
infect
clear
differ
virus
sever
ill
ili
episod
medic
attend
ili
associ
influenza
result
highest
proport
children
miss
school
daycar
although
children
infect
virus
also
miss
school
daycar
differ
virus
proport
children
hospit
clinic
featur
variabl
depend
upon
viral
infect
associ
ili
episod
studi
limit
describ
previous
healthi
children
particip
trial
limit
generaliz
addit
studi
includ
children
age
month
limit
number
children
age
month
find
mainli
relev
older
children
fever
part
ili
definit
therefor
would
miss
case
children
fever
put
perspect
influenza
incid
surveil
project
case
among
children
age
year
year
respect
met
arti
definit
requir
fever
meet
ili
definit
requir
fever
howev
definit
ili
somewhat
broader
except
children
year
age
us
data
may
generaliz
tropic
southern
hemispher
countri
studi
inclus
healthi
children
studi
exclus
case
fever
would
underestim
burden
also
could
discrimin
rhinoviru
enteroviru
pcr
therefor
exact
preval
incid
one
could
determin
final
studi
includ
small
number
pneumonia
case
n
z
limit
conclus
drawn
regard
distribut
viral
infect
case
overal
pneumonia
detect
rate
clinic
trial
higher
line
report
us
hospit
case
howev
sampl
collect
rate
among
pneumonia
case
compar
ili
overal
conclus
activ
surveil
healthi
children
part
vaccin
efficaci
trial
provid
evid
burden
respiratori
ill
associ
rang
virus
substanti
burden
ill
occur
older
children
data
epidemiolog
respiratori
virus
determin
activ
surveil
healthi
children
gener
lack
particularli
spars
develop
countri
includ
studi
consider
amount
burden
would
identifi
hospitalbas
surveil
novel
data
fill
import
gap
knowledg
epidemiolog
virus
contribut
substanti
burden
respiratori
diseas
children
may
use
inform
prioriti
implement
exist
vaccin
program
develop
new
vaccin
work
support
glaxosmithklin
biolog
sa
sponsor
studi
involv
stage
studi
conduct
includ
analysi
data
addit
paid
cost
relat
develop
public
manuscript
